PubMed Health⌕ Search

Biomedical subjects

O Cars

Publications and source records attributed to O Cars.

96 records · Page 6Linked to original sources
PubMed1976

A retrospective study of the occurrence of beta-haemolytic streptococci of various Lancefield groups in routine cultures from the County of Uppsala.

During the months October to December of the years 1971-1974 the incidence of beta-haemolytic streptococci of the Lancefield groups, A, B, C and G from patients in the County of Uppsala was studied. The proportion of culture positive patients increased during the period studied from 7.2% to 13.7%. The increase was not only due to group A. In cultures from the respiratory tract the finding of group A streptococci increased from 4.1% to 10.7% and group C from 0.1% to 1.6%, while group B and G streptococci remained constant. In cultures from wound infections the percentage of patients culture positive for group A streptococci increased from 6.2% to 8.7%, group B from 0.8% to 1.9%, and group G from 0.5% to 0.9%, while group C remained constant. During the same months of the years 1972 to 1974 the frequency of sera with an antistreptolysin O titre of more than 1 000 U/ml increased from 0.6% t0 2.3% in the same region. A clinical study of scarlet fever and pharyngotonsillitis at the Department of Infectious Diseases showed a similar trend concerning group A streptococcal infections. These results stress the great importance of group A beta-haemolytic streptocci in human infections and indicate that the recent interest in non-group A infections should be continued.

Bacteriological Techniques↗
PubMed1975

New immunofluorescence method for the identification of group a, b, c, e, and g streptococci.

An immunofluorescence method for the identification of groups A, B, C, E, F, and G beta-haemolytic streptococci has been developed, using FITC-labelled F(ab')2 fragments of IgG with optimal staining characteristics. The method is useful for the rapid confirmation of beta-haemolytic streptococci in cultures; in a blind comparison with Lancefield grouping, there was a 97 per cent agreement.

Animals↗
PubMed1975

Alpha-1-antitrypsin deficiency, mitochondrial antibodies and possible primary biliary cirrhosis. A case report and family study.

A case of a 70-year-old woman with a history of gastric ulcer and several pneumonias is presented. She was found to have pulmonary emphysema, severe alpha-1-antitrypsin (alpha1AT) deficiency and raised serum mitochondrial antibodies. Surgical liver biopsy showed portal liver cirrhosis, PAS-positive, diastaseresistant globules in the hepatocytes and changes interpreted as florid duct lesion of primary biliary cirrhosis. A brother has severe alpha1AT deficiency. Two daughters had raised mitochondrial antibodies. One of the latter had a granulomatous hepatitis, a common finding in primary biliary cirrhosis. The association of alpha1AT deficiency and primary biliary cirrhosis does not seem to have been described previously.

Adolescent↗
PubMedDate not supplied

Randomized comparison of aztreonam and cefuroxime in gram-negative upper urinary tract infections.

In order to evaluate the efficacy and safety of aztreonam in hospitalized patients with upper urinary tract infections (UTI), a comparative clinical study with cefuroxime was performed. 62/60% (aztreonam/cefuroxime) of the patients had a complicating factor, mostly obstructive uropathy. I.v. bolus injections were used at a dose of 1 g aztreonam or 1.5 g cefuroxime t.i.d., for a mean of 8.2 days (range: five to 14 days) except in patients with bacteraemia, who received a mean of 10.3 days (range: seven to 13 days) of therapy. 89% of the patients treated with aztreonam and 87% of those who received cefuroxime showed clinical cure and the bacteriological cure rate at one week post-therapy was 70% and 73% in the respective groups. The relapse/reinfection rate was high with both drugs; bacteriological cure at one month post-therapy was only 43% after aztreonam and 40% after cefuroxime. This suggests that these infections may need longer treatment times. Superinfections, mostly asymptomatic urinary colonization, occurred in 7% and 3%, respectively, and adverse reactions in 23% and 12%, respectively, of the patients treated with aztreonam or cefuroxime, the majority being mild and reversible and only 3% and 3%, respectively, requiring discontinuation of the therapy. The t 1/2 for aztreonam following a 1 g i.v. bolus was 2.0 h in six patients with creatinine clearance above 80 ml/min and 3.0 h in seven patients with creatinine clearance between 35-75 ml/min.

Adolescent↗
PubMedDate not supplied

Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics.

The study of pharmacokinetics teaches us how drugs are distributed and eliminated, whereas, pharmacodynamics looks at the relationship between drug concentration and drug activity. The free, nonprotein-bound fraction of the serum concentration can be used as a surrogate marker for the levels at the site of infection. It is tempting to use tissue levels for this purpose, but their use is fraught with difficulties. The single pharmacodynamic parameter that correlates best with therapeutic efficacy for beta-lactam antibiotics is time that free serum levels stay above the minimum inhibitory concentration (MIC). Recent clinical studies seem to confirm the value of time above MIC in predicting clinical and bacteriological outcome.

Animals↗